Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody

Kidney Int. 2019 Jan;95(1):233-234. doi: 10.1016/j.kint.2018.08.045.

¹ AP-HP, Hôpital Tenon, Department of Nephrology and Dialysis, Paris, France; CRMR, Centre de référence maladies rares "Syndrome Néphrotique Idiopathique de l'Enfant et de l'Adulte," Hôpital Tenon, Paris, France. Electronic address: karine.dahan@aphp.fr.
² AP-HP, Hôpital Saint Antoine, Department of immunology, Paris, France.
³ AP-HP, Hôpital Tenon, Department of Nephrology and Dialysis, Paris, France; Sorbonne Universités, UPMC Univ Paris 06, Paris, France; INSERM, Paris, France.
⁴ AP-HP, Hôpital Tenon, Department of Nephrology and Dialysis, Paris, France; CRMR, Centre de référence maladies rares "Syndrome Néphrotique Idiopathique de l'Enfant et de l'Adulte," Hôpital Tenon, Paris, France; Sorbonne Universités, UPMC Univ Paris 06, Paris, France; INSERM, Paris, France.
⁵ Sorbonne Universités, UPMC Univ Paris 06, Paris, France; INSERM, Paris, France.

No abstract available

Publication types